Stay updated with breaking news from Engagers Tces. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boehringer Ingelheim today announced the acquisition of privatelyheld T3 Pharmaceuticals AG T3 Pharma a clinical stage Swiss biotech company for an amount of up to 450 million CHF.
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer ...
Spearheading Immunotherapies CORPORATE PRESENTATION MARCH 28, 2023 Nasdaq: HARP Forward-looking... | March 29, 2023
Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies
Scoop Community provides New Zealand Community news and views